First-in-Class Novel Therapy for Chronic Myelomonocytic Leukemia Granted FDA Orphan Drug Designation
Immune-Onc Therapeutics’ IO-202 is currently being analyzed as a monotherapy and in combination for patients with relapsed/refractory acute myeloid leukemia with monocytic differentiation or chronic myelomonocytic leukemia.
Image credit: Tada Images | stock.adobe.com
Immune-Onc Therapeutics’ novel therapy IO-202 has been granted orphan drug designation by the FDA to treat patients with chronic myelomonocytic leukemia (CMML).1 The first-in-class, humanized IgG1 antibody is currently being analyzed in a Phase I trial (NCT04372433) both as a monotherapy and in combination with Vidaza (azacitidine) with or without Venclexta (venetoclax) in patients with relapsed/refractory acute myeloid leukemia (AML) with monocytic differentiation or CMML.
“Although current therapeutic options for CMML can improve a patient’s quality of life, there is a high unmet need for effective disease-modifying approaches that are potentially curative,” Immune-Onc CEO and board chair Charlene Liao PhD, said in a news release. “We are very proud that the FDA has granted IO-202 orphan drug designation for the treatment of [patients with] CMML. We look forward to continued collaborations with our investigators and the FDA as we work to bring this potentially important therapy to patients with hard-to-treat blood cancers.”1
IO-202 was developed for high-affinity binding to leukocyte immunoglobulin-like receptor subfamily B4.1 Eligibility criteria for the multicenter, open-label trial included being at least 18 years of age, an ECOG performance status of 2 or lower, adequate hepatic and renal function, and not having received systemic calcineurin inhibitors for at least four weeks prior to administration of IO-202.2
During the dose-escalation portion of the trial, patients were administered intravenous IO-202 in dose levels that ranged from 0.03 mg/kg to 60 mg/kg on days one and 15 of each 28-day cycle, and administration of Vidaza at 75 mg/m2 on days one through seven of each cycle.
The trial’s primary endpoints were safety and tolerability of the novel agent both as a monotherapy and combined with Vidaza with or without Venclexta, with secondary endpoints that included pharmacokinetics, response rates, and incidence of antidrug antibodies against the study therapy.2
Investigators concluded that IO-202 was safe and well tolerated with promising efficacy at a maximum dose of 60 mg/kg twice weekly as monotherapy and combined with Vidaza.
IO-202 was granted Fast Track designation by the FDA in 2023 for patients with relapsed/refractory CMML.Further, IO-202 received FDA Fast Track designation in 2022 to treat patients with relapsed/refractory AML. In 2020, the FDA awarded the therapy with Orphan Drug designation for the same indication.1
References
1. Immune-Onc Therapeutics announces orphan drug designation granted by US FDA for IO-202 (anti-LILRB4) for the treatment of chronic myelomonocytic leukemia (CMML). News release. Immune-Onc Therapeutics, Inc. February 21, 2024. Accessed February 22, 2024. https://www.businesswire.com/news/home/20240221174545/en
2. IO-202 as monotherapy and IO-202 plus azacitidine ± venetoclax in patients in AML and CMML. ClinicalTrials.gov. Updated January 8, 2024. Accessed February 22, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT04372433
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
